Reports Q2 revenue $214M, consensus $206.99M. “I am extremely proud of the revenue growth in the first half of 2023 providing us confidence that we will meet our full-year total revenue guidance,” said CEO Matthew Klein. “In addition, the great results from the APHENITY and PIVOT-HD trials position us well for future growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PTCT:
- PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
- Fennec appoints Adrian Haigh as COO
- PTC Therapeutics says CHMP adopts positive opinion for Evrysdi
- PTC Therapeutics sees Upstaza BLA submission in Q3
- PTC Therapeutics still sees FY23 revenue $940M-$1B, consensus $961.42M